JP2009534358A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009534358A5 JP2009534358A5 JP2009505894A JP2009505894A JP2009534358A5 JP 2009534358 A5 JP2009534358 A5 JP 2009534358A5 JP 2009505894 A JP2009505894 A JP 2009505894A JP 2009505894 A JP2009505894 A JP 2009505894A JP 2009534358 A5 JP2009534358 A5 JP 2009534358A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally
- group
- substituted
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 19
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- 229920006395 saturated elastomer Polymers 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 13
- 125000005842 heteroatom Chemical group 0.000 claims 13
- 229910052717 sulfur Chemical group 0.000 claims 13
- 239000011593 sulfur Chemical group 0.000 claims 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 239000001301 oxygen Substances 0.000 claims 12
- 125000002619 bicyclic group Chemical group 0.000 claims 7
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- -1 carboxy, amino Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 230000011987 methylation Effects 0.000 claims 3
- 238000007069 methylation reaction Methods 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 229960005305 adenosine Drugs 0.000 claims 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical group 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims 1
- 239000012346 acetyl chloride Substances 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0607944.6A GB0607944D0 (en) | 2006-04-21 | 2006-04-21 | Organic compounds |
| PCT/EP2007/053847 WO2007147659A1 (en) | 2006-04-21 | 2007-04-19 | Adenosine a3 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009534358A JP2009534358A (ja) | 2009-09-24 |
| JP2009534358A5 true JP2009534358A5 (enExample) | 2011-03-10 |
Family
ID=36581041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009505894A Pending JP2009534358A (ja) | 2006-04-21 | 2007-04-19 | アデノシンａ３受容体アゴニスト |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090281126A1 (enExample) |
| EP (1) | EP2013199A1 (enExample) |
| JP (1) | JP2009534358A (enExample) |
| KR (1) | KR20080110845A (enExample) |
| CN (1) | CN101426785A (enExample) |
| AU (1) | AU2007263237B2 (enExample) |
| BR (1) | BRPI0710514A2 (enExample) |
| CA (1) | CA2649648A1 (enExample) |
| GB (1) | GB0607944D0 (enExample) |
| MX (1) | MX2008013520A (enExample) |
| RU (1) | RU2008145708A (enExample) |
| WO (1) | WO2007147659A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| WO2007121920A2 (en) | 2006-04-21 | 2007-11-01 | Novartis Ag | Purine derivatives for use as adenosin a2a receptor agonists |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607954D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| US20100041918A1 (en) * | 2006-11-10 | 2010-02-18 | Novartis Ag | Cyclopentene diol monoacetate derivatives |
| CN101827847A (zh) * | 2007-10-17 | 2010-09-08 | 诺瓦提斯公司 | 用作腺苷a1受体配体的嘌呤衍生物 |
| WO2009123881A1 (en) | 2008-03-31 | 2009-10-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as a3 receptor- selective agonists |
| US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
| US8796291B2 (en) | 2008-08-01 | 2014-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
| US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1528382A (en) * | 1974-12-26 | 1978-10-11 | Teijin Ltd | Cyclopentene diols and acyl esters thereof and processes for their preparation |
| US4738954A (en) * | 1985-11-06 | 1988-04-19 | Warner-Lambert Company | Novel N6 -substituted-5'-oxidized adenosine analogs |
| US4954504A (en) * | 1986-11-14 | 1990-09-04 | Ciba-Geigy Corporation | N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity |
| US5688774A (en) * | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| BR9612341A (pt) * | 1996-01-02 | 1999-12-28 | Rhone Poulenc Rorer Pharma | Processo para preparar 2,4-diidróxipiridina. |
| US6376472B1 (en) * | 1996-07-08 | 2002-04-23 | Aventis Pharmaceuticals, Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| GB9813554D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| KR20010089751A (ko) * | 1998-12-31 | 2001-10-08 | 오흘러 로스 제이. | Ｎ6-치환된 데아자-아데노신 유도체의 제조방법 |
| US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
| US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| US6586413B2 (en) * | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| BR0206492A (pt) * | 2001-01-16 | 2004-02-10 | Can Fite Biopharma Ltd | Composição farmacêutica para inibir a replicação de um vìrus dentro de células, uso de pelo menos um agonista receptor de adenosina a3, e, métodos para inibir a replicação de um vìrus em células |
| US20040162422A1 (en) * | 2001-03-20 | 2004-08-19 | Adrian Hall | Chemical compounds |
| EP1258247A1 (en) * | 2001-05-14 | 2002-11-20 | Aventis Pharma Deutschland GmbH | Adenosine analogues for the treatment of insulin resistance syndrome and diabetes |
| US7414036B2 (en) * | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| PL1699459T3 (pl) * | 2003-12-29 | 2007-12-31 | Can Fite Biopharma Ltd | Sposób leczenia stwardnienia rozsianego |
| US7825102B2 (en) * | 2004-07-28 | 2010-11-02 | Can-Fite Biopharma Ltd. | Treatment of dry eye conditions |
| EP1778239B1 (en) * | 2004-07-28 | 2013-08-21 | Can-Fite Biopharma Ltd. | Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome |
| CN101056879B (zh) * | 2004-09-09 | 2011-10-05 | 美国政府卫生与公共服务部 | 作为a3和a1腺苷受体激动剂的嘌呤衍生物 |
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| US7176172B2 (en) * | 2004-10-25 | 2007-02-13 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Quaternary ammonium polyol salts as anti-aging actives in personal care compositions |
| US20080051364A1 (en) * | 2004-11-08 | 2008-02-28 | Pninna Fishman | Therapeutic Treatment of Accelerated Bone Resorption |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| EP1848718B1 (en) * | 2005-02-04 | 2012-08-01 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
| CA2622879C (en) * | 2005-11-30 | 2011-07-05 | Can-Fite Biopharma Ltd. | Use of a3 adenosine receptor agonist in osteoarthritis treatment |
| DK1983990T3 (da) * | 2006-01-26 | 2011-07-11 | Us Gov Health & Human Serv | Allosteriske A3-adenosin-receptormodulatorer |
| CN106008512B (zh) * | 2006-02-02 | 2019-03-12 | 千禧药品公司 | E1活化酶抑制剂 |
| WO2007121920A2 (en) * | 2006-04-21 | 2007-11-01 | Novartis Ag | Purine derivatives for use as adenosin a2a receptor agonists |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607954D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607951D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| EP1889846A1 (en) * | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| US8008307B2 (en) * | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| US20100041918A1 (en) * | 2006-11-10 | 2010-02-18 | Novartis Ag | Cyclopentene diol monoacetate derivatives |
| US20090181934A1 (en) * | 2007-10-17 | 2009-07-16 | Novartis Ag | Organic Compounds |
| CN101827847A (zh) * | 2007-10-17 | 2010-09-08 | 诺瓦提斯公司 | 用作腺苷a1受体配体的嘌呤衍生物 |
-
2006
- 2006-04-21 GB GBGB0607944.6A patent/GB0607944D0/en not_active Ceased
-
2007
- 2007-04-19 US US12/296,714 patent/US20090281126A1/en not_active Abandoned
- 2007-04-19 CA CA002649648A patent/CA2649648A1/en not_active Abandoned
- 2007-04-19 AU AU2007263237A patent/AU2007263237B2/en not_active Ceased
- 2007-04-19 WO PCT/EP2007/053847 patent/WO2007147659A1/en not_active Ceased
- 2007-04-19 MX MX2008013520A patent/MX2008013520A/es not_active Application Discontinuation
- 2007-04-19 EP EP07845239A patent/EP2013199A1/en not_active Withdrawn
- 2007-04-19 CN CNA2007800142903A patent/CN101426785A/zh active Pending
- 2007-04-19 BR BRPI0710514-2A patent/BRPI0710514A2/pt not_active IP Right Cessation
- 2007-04-19 JP JP2009505894A patent/JP2009534358A/ja active Pending
- 2007-04-19 RU RU2008145708/04A patent/RU2008145708A/ru not_active Application Discontinuation
- 2007-04-19 KR KR1020087025605A patent/KR20080110845A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009534358A5 (enExample) | ||
| TWI795362B (zh) | 拮抗藥與免疫核查點阻礙藥而成之組合 | |
| TWI812496B (zh) | 三環性螺化合物之用途 | |
| JP2014506599A5 (enExample) | ||
| AU2018221820A1 (en) | Processes for the preparation of benzodiazepine derivatives | |
| WO2001085730A1 (en) | Pyrido' 1,2-alpha pyrazine and piperidine derivatives as ligands for the neuropeptide y y5 receptor | |
| JP2016506962A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| JP2005537255A5 (enExample) | ||
| JP2016535732A5 (enExample) | ||
| WO2008005914A3 (en) | Novel glucokinase activators and methods of using same | |
| EP1829858A3 (en) | Dibenzylamine compounds and pharmaceutical use thereof | |
| JP2017533968A5 (enExample) | ||
| JP2020521767A5 (enExample) | ||
| JP2013508373A5 (enExample) | ||
| KR102519536B1 (ko) | 트리시클릭 회전장애이성질체 화합물 | |
| JP2011513410A5 (enExample) | ||
| JP2006502119A5 (enExample) | ||
| JP2012522766A5 (enExample) | ||
| CA2654315A1 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and their use | |
| JP2006507355A5 (enExample) | ||
| WO2004020430A3 (fr) | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique | |
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
| EP3296309A8 (en) | Galactopyranosyl derivatives useful as medicaments | |
| JP2005517008A5 (enExample) |